Cytokine receptor-like factor 2 (CRLF2) encodes for a receptor
protein that participates in activating
STAT, possibly through JAK pathways. These pathways are important in immune system regulation. In cancer, CRLF2 rearrangements
and one recurring mutation leading to
CRLF2 overexpression have been identified in a subset of patients with high risk acute
lymphoblastic leukemia who have an exceptionally dismal prognosis.
JAK and mTOR inhibitors have been explored in preclinical models as potential therapies
targeting CRLF2-rearranged ALL (Maude
et al. 2011; Tasian et al. 2012).
Brown, V., Borinstein, S.C., Friedman, D. 2015.
My Cancer Genome
(Updated December 2015)
December 7, 2015
Disclaimer: The information presented at padiracinnovation.org is compiled from sources
believed to be reliable. Extensive efforts have been made to make this information as accurate and as
up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed.
Despite our best efforts, this information may contain typographical errors and omissions. The contents
are to be used only as a guide, and health care providers should employ sound clinical judgment in
interpreting this information for individual patient care.